큐레이션 · 헬스케어

Big pharma

InspectStocks 제공Published 2026년 10월 14일13 companies0 followers

The largest drugmakers, selling prescription medicines worldwide.

AI 모델의 도움으로 묶고 편집자가 검토했습니다. 각 기업 아래의 한 줄이 이 기업이 여기 있는 이유를 설명합니다.

Download image

카드 티어

주가는 2026년 11월 11일 종가이며, IEX 거래소 피드 기준입니다.

Grade mix

A 7B 3C 3

Revenue growing

12 of 12

Free cash flow growing

9 of 13

Median price move, 1 year

+34.0%

Sort by

LLYELI LILLY AND COMPANY
Drug manufacturers generalMarket cap US$1.35TP/E 46.67
US$1,437.79+42.2%1Y
Since added +23.2%
A+
성장과 현금
강하게 성장 중
Business trend
안정
Business quality
우수
Getting better
개선 중
Revenue
US$86.5B+45.5%
Profit
US$27.6B+49.8%
Free cash flow
US$19.7B+112.1%
Discuss
Why it is here: Sells prescription medicines for diabetes, obesity, cancer and inflammation
JNJJohnson & Johnson
Drug manufacturers generalMarket cap US$674.9BP/E 42.54
US$280.34+47.5%1Y
Since added +12.8%
A+
성장과 현금
강하게 성장 중
Business trend
안정
Business quality
우수
Getting better
혼조
Revenue
US$99.3B+7.8%
Profit
US$16.1B-35.9%
Free cash flow
US$20.6B+5.1%
Discuss
Why it is here: Sells prescription medicines for cancer and immune disorders
ABBVAbbVie Inc.
Drug manufacturers generalMarket cap US$521.2BP/E 50.75
US$294.87+30.2%1Y
Since added +7.5%
B+
성장과 현금
강하게 성장 중
Business trend
안정
Business quality
우수
Getting better
개선 중
Revenue
US$66B+10.7%
Profit
US$10.3B+333.1%
Free cash flow
US$18.9B-4.1%
Discuss
Why it is here: Sells medicines for immune, neurological and cancer conditions
MRKMerck & Co., Inc.
Drug manufacturers generalMarket cap US$362.9BP/E 150.20
US$147.20+65.7%1Y
Since added +3.7%
A
성장과 현금
강하게 성장 중
Business trend
안정
Business quality
양호
Getting better
혼조
Revenue
US$67.4B+4.9%
Profit
US$2.5B-87.1%
Free cash flow
US$14.7B+13.0%
Discuss
Why it is here: Sells prescription medicines and vaccines for people and animals
NVSNovartis AG
Drug manufacturers generalMarket cap US$306BP/E 없음 (영업손실)
US$160.36+23.6%1Y
Since added +12.6%
A
성장과 현금
강하게 성장 중
Business quality
혼조
Getting better
크게 개선 중
Revenue
US$56.7B+9.6%
Profit
-US$46MNo comparable year
Free cash flow
US$17.6B+8.3%
Discuss
Why it is here: Sells prescription medicines
AZNASTRAZENECA PLC
Drug manufacturers generalMarket cap US$289.7BP/E 28.36
US$185.49+115.2%1Y
Since added +19.0%
B+
성장과 현금
강하게 성장 중
Business trend
둔화
Business quality
우수
Getting better
크게 개선 중
Revenue
US$62.4B+7.3%
Profit
US$10.2B+45.3%
Free cash flow
US$11.8B+18.4%
Discuss
Why it is here: Sells prescription medicines
NVONOVO NORDISK A/S
Drug manufacturers generalMarket cap US$182.8BP/E 11.84
US$41.10-15.4%1Y
Since added +8.0%
C+
성장과 현금
성장 중
Business trend
가속
Business quality
우수
Getting better
개선 중
Revenue
US$50.3B+5.7%
Profit
US$17.1B+9.1%
Free cash flow
US$8.9B-20.1%
Discuss
Why it is here: Sells diabetes and obesity medicines
PFEPFIZER INC
Drug manufacturers generalMarket cap US$167.9BP/E 42.07
US$29.45+21.4%1Y
Since added +3.8%
C
성장과 현금
강하게 성장 중
Business trend
축소
Business quality
양호
Getting better
혼조
Revenue
US$63.6B+1.3%
Profit
US$4B-59.0%
Free cash flow
US$11.8B+13.6%
Discuss
Why it is here: Sells prescription medicines and vaccines
BMYBRISTOL-MYERS SQUIBB COMPANY
Drug manufacturers generalMarket cap US$128.6BP/E 13.95
US$62.92+34.0%1Y
Since added +11.0%
C+
성장과 현금
성장 중
Business trend
안정
Business quality
우수
Getting better
크게 개선 중
Revenue
US$50B+4.2%
Profit
US$9.2B+53.1%
Free cash flow
US$9.3B-39.3%
Discuss
Why it is here: Sells prescription medicines for cancer and immune conditions
SNYSanofi
Drug manufacturers generalMarket cap US$59.1BP/E 6.81
US$48.43-3.0%1Y
Since added +23.9%
B
성장과 현금
강하게 성장 중
Business trend
안정
Business quality
혼조
Getting better
개선 중
Revenue
US$53.5B+11.6%
Profit
US$4.7B-54.2%
Free cash flow
US$8.1B+22.5%
Discuss
Why it is here: Sells prescription medicines and vaccines
GSKGSK plc
Drug manufacturers generalMarket cap US$109.2BP/E 13.60
US$50.60+8.9%1Y
Since added +9.3%
A+
성장과 현금
강하게 성장 중
Business quality
우수
Getting better
크게 개선 중
Revenue
US$43.8B+4.1%
Profit
US$7.7B+122.0%
Free cash flow
US$8.6B+24.0%
Discuss
Why it is here: Sells prescription medicines and vaccines worldwide
AMGNAmgen Inc.
Drug manufacturers generalMarket cap US$253.2BP/E 27.14
US$468.13+43.1%1Y
Since added +13.4%
A+
성장과 현금
강하게 성장 중
Business trend
안정
Business quality
우수
Getting better
개선 중
Revenue
US$38.9B+8.2%
Profit
US$9.4B+34.1%
Free cash flow
US$9.6B-17.0%
Discuss
Why it is here: Develops and sells medicines and biosimilars for serious diseases
TAKTakeda Pharmaceutical Company Limited
Drug manufacturers specialty and genericMarket cap US$33.5BP/E 48.79
US$20.86+50.1%1Y
Since added +12.5%
A
성장과 현금
강하게 성장 중
Business quality
혼조
Getting better
혼조
Revenue
US$29.8BNo comparable year
Profit
US$259.4MNo comparable year
Free cash flow
US$5.5B+1.1%
Discuss
Why it is here: Sells prescription medicines and vaccines globally

Green and red compare each figure with the same window a year earlier. Grades and checks are the company page's own; nothing here is a recommendation.

DiscussionNo comments yet

Be civil and stick to the companies. Comments are opinions, not advice.

Lists are their owners' own, and notes and comments are opinions. Grades describe businesses from their filings; nothing here is a recommendation to buy or sell.